scholarly journals The association between histological subtype of a first primary endometrial cancer and second cancer risk

2018 ◽  
Vol 29 (2) ◽  
pp. 290-298
Author(s):  
Jennifer Rhoades ◽  
Monica Hagan Vetter ◽  
James L Fisher ◽  
David E Cohn ◽  
Ritu Salani ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
General Population ◽  
Cancer Risk ◽  
Second Primary ◽  
Low Grade ◽  
Primary Cancer ◽  
Histological Subtype ◽  
Second Primary Cancer ◽  
Histological Subtypes ◽  
Cancer Risks

ObjectiveTo evaluate the risk of a second primary cancer after endometrial cancer according to histological subtype.MethodsUsing data from the 13 National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) registries we identified women diagnosed with a primary endometrial cancer between 1992 and 2014. We calculated standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for second primary cancer risk (all anatomical sites combined and for individual anatomical sites) among patients with endometrial cancer compared with the general population, in the overall study population and according to histological subtype.ResultsAmong 96 256 women diagnosed with endometrial cancer, 8.4% (n=8083) developed a second primary cancer. The risk of second primary cancer was higher among patients with endometrial cancer than in the general population (SIR=1.05, 95% CI 1.03 to 1.07). We observed significantly higher second primary cancer risk among women with high grade endometrioid (SIR=1.12, 95% CI 1.05 to 1.19), serous (SIR=1.24, 95% CI 1.11 to 1.38), carcinosarcoma (SIR=1.18, 95% CI 1.02 to 1.35), mixed epithelial (SIR=1.22, 95% CI 1.06 to 1.40), and sarcoma (SIR=1.28, 95% CI 1.12 to 1.45) compared with the general population, but not for women with low grade endometrioid (SIR=1.01, 95% CI 0.98 to 1.03) or clear cell (SIR=1.09, 95% CI 0.88 to 1.33) endometrial cancer. Women with low grade endometrioid endometrial cancer had significantly lower second primary cancer risks in the gum and other mouth (SIR=0.57, 95% CI 0.30 to 0.97), lung and bronchus (SIR=0.72, 95% CI 0.66 to 0.77), and lymphocytic leukemia (SIR=0.71, 95% CI 0.54 to 0.93) while women with high risk endometrial cancer histological subtypes experienced significantly higher second primary cancer risk at several anatomical sites.ConclusionsRisk of developing second primary cancersat all anatomic sites combined and at individual anatomical sites varied according to histological subtype. Clinicians should be aware that women with different histological subtypes carry different second primary cancer risks .

scholarly journals The effect of patient characteristics on second primary cancer risk in France

BMC Cancer ◽  
2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Jérémie Jégu ◽  
Marc Colonna ◽  
Laetitia Daubisse-Marliac ◽  
Brigitte Trétarre ◽  
Olivier Ganry ◽  
...  
Keyword(s):  
Cancer Risk ◽  
Patient Characteristics ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer

Development of second primary cancers in breast cancer survivors.

2016 ◽  
Vol 34 (3_suppl) ◽  
pp. 257-257
Author(s):  
Hong Kyu Jung ◽  
Jihyoun Lee ◽  
Zisun Kim ◽  
Min Hyuk Lee ◽  
Ilkyun Lee
Keyword(s):  
Breast Cancer ◽  
Endometrial Cancer ◽  
Thyroid Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer ◽  
Breast Cancer Patients ◽  
Second Primary Cancers

257 Background: Breast cancer survivors have slightly increased risk of second primary cancers. Importance of screening for second cancers has been raised due to increased survival in those populations. Not only having genetic risk such as BRCA mutation, but also treatment-related risk presents. The most common second primary cancer is breast cancer. Colon cancer, uterine cancer, and ovarian cancer showed increased cumulative incidence. In this study, we assessed development second primary cancers in breast cancer survivors. Methods: Medical record of breast cancer patients was reviewed retrospectively in three tertiary medical institutions. Available data of ICD-9 record after breast cancer diagnosis was evaluated. Diagnosis of second primary breast cancer was excluded in evaluation. Results: Since Jan 1989 to Jan 2014, available medical records were reviewed in breast cancer patients(N = 5880) in three institutions(one urban and the other two rural institutions). Cumulative incidence of overall second primary cancers was 4.57%. Among 269 second primary cancers, thyroid cancer(44.2%) was most common second primary cancer, followed by gastric cancer(10.0%). Gastric cancers were more common in rural institution than urban area(14.2 % vs 5.5%), while incidence of thyroid cancer is elevated in urban institution(57.8% vs 31.9%). Among 9 patients who has been diagnosed endometrial cancer, 7 patients had history of selective estrogen receptor modulator(tamoxifen or toremifen) treatment. Development of lung cancer was not related to breast cancer radiation treatment(4 of 15 patients). Leukemia after breast cancer treatment was diagnosed in 5 patients (8.5% of second primary cancers), three of them were adult T cell leukemia and two of them were acute myeloid leukemia. Conclusions: Incidence of cancer in general population was reflected to development of second primary cancer in breast cancer survivors. Endocrine treatment was related increased incidence of endometrial cancer, respectively. Application of personalized cancer screening plan would be important in this patient group.

Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma

Thyroid ◽  
2017 ◽  
Vol 27 (2) ◽  
pp. 261-270 ◽  
Author(s):  
Nilton Lavatori Corrêa ◽  
Lidia Vasconcellos de Sá ◽  
Rossana Corbo Ramalho de Mello
Keyword(s):  
Cancer Risk ◽  
Thyroid Carcinoma ◽  
Radioactive Iodine ◽  
Differentiated Thyroid Carcinoma ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer

Time from incident primary cancer until recurrence or second primary cancer: Risk factors and impact in general practice

2019 ◽  
Vol 28 (5) ◽  
Author(s):  
Linda Aagaard Rasmussen ◽  
Henry Jensen ◽  
Line Flytkjær Virgilsen ◽  
Alina Zalounina Falborg ◽  
Henrik Møller ◽  
...  
Keyword(s):  
Risk Factors ◽  
General Practice ◽  
Cancer Risk ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer ◽  
Cancer Risk Factors

Prostate Brachytherapy and Second Primary Cancer Risk: A Competitive Risk Analysis

2011 ◽  
Vol 29 (34) ◽  
pp. 4510-4515 ◽  
Author(s):  
Karel A. Hinnen ◽  
Michael Schaapveld ◽  
Marco van Vulpen ◽  
Jan. J. Battermann ◽  
Henk van der Poel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Rectal Cancer ◽  
General Population ◽  
Lead Time ◽  
Incidence Rates ◽  
Second Primary ◽  
Prostate Brachytherapy ◽  
Primary Cancer ◽  
Second Primary Cancer

Purpose To assess the risk of second primary cancer (SPC) after [125I]iodine prostate cancer brachytherapy compared with prostatectomy and the general population. Patients and Methods In a cohort consisting of 1,888 patients with prostate cancer who received monotherapy with brachytherapy (n = 1,187; 63%) or prostatectomy (n = 701; 37%), SPC incidences were retrieved by linkage with the Dutch Cancer Registry. Standardized incidence rates (SIRs) and absolute excess risks (AERs) were calculated for comparison. Results A total of 223 patients were diagnosed with SPC, 136 (11%) after brachytherapy and 87 (12%) after prostatectomy, with a median follow-up of 7.5 years. The SIR for all malignancies, bladder cancer, and rectal cancer were 0.94 (95% CI, 0.78 to 1.12), 1.69 (95% CI, 0.98 to 2.70), and 0.90 (95% CI, 0.41 to 1.72) for brachytherapy and 1.04 (95% CI, 0.83 to 2.28), 1.82 (95% CI, 0.87 to 3.35), and 1.50 (95% CI, 0.68 to 2.85) for prostatectomy, respectively. Bladder SPC risk was significantly increased after brachytherapy for patients age 60 years or younger (SIR, 5.84; 95% CI, 2.14 to 12.71; AER, 24.03) and in the first 4 years of follow-up (SIR, 2.14; 95% CI, 1.03 to 3.94; AER, 12.24). Adjusted for age, the hazard ratio (brachytherapy v prostatectomy) for all SPCs combined was 0.87 (95% CI, 0.64 to 1.18). Conclusion Overall, we found no difference in SPC incidence between patients with prostate cancer treated with prostatectomy or brachytherapy. Furthermore, no increased tumor incidence was found compared with the general population. We observed a higher than expected incidence of bladder SPC after brachytherapy in the first 4 years of follow-up, probably resulting from lead time or screening bias. Because of power limitations, a small increased SPC risk cannot be formally excluded.

scholarly journals Second primary cancers and recurrence in patients after resection of colorectal cancer: An integrated analysis of trials by Japan Clinical Oncology Group: JCOG1702A

2020 ◽  
Author(s):  
Kiyo Tanaka ◽  
Gakuto Ogawa ◽  
Junki Mizusawa ◽  
Tomohiro Kadota ◽  
Kenichi Nakamura ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
General Population ◽  
Cumulative Incidence ◽  
National Database ◽  
Integrated Analysis ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer ◽  
Surveillance Strategy ◽  
Second Primary Cancers

Abstract Background Improvements in early detection and treatment have resulted in an increasing number of long-term survivors of colorectal cancer (CRC). For the survivors, second primary cancer and recurrence are important issues; however, evidence for an appropriate surveillance strategy remains limited. This study aimed to investigate the frequency and timing of second primary cancer in patients after surgery for exploring an appropriate surveillance strategy by using an integrated analysis of three large-scale randomized controlled trials in Japan. Methods The eligibility criteria of three trials included histologically confirmed CRC and having received surgery. The timing, site and frequency of second primary cancers and recurrence were investigated. Risk factors associated with second primary cancers were also examined. The standardized incidence ratio (SIR) of second primary cancers compared with the national database of the Japan Cancer Registry was estimated. Results A total of 2824 patients were included in this study. The cumulative incidence of second primary cancer increased over time. The SIR of any second primary cancer was 1.07 (95% CI: 0.94–1.21). The SIR for second primary cancers of colon was 1.09 (95% CI: 0.79–1.47). The cumulative incidence of recurrence almost reached plateau at 3 years. Conclusions A common surveillance strategy for the general population can be applied even for curatively resected CRC patients, as the risk of second primary cancers was almost the same as that of the general population.

Sign in / Sign up

Export Citation Format

Share Document